Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCRX logo BCRX
Upturn stock ratingUpturn stock rating
BCRX logo

BioCryst Pharmaceuticals Inc (BCRX)

Upturn stock ratingUpturn stock rating
$9.96
Last Close (24-hour delay)
Profit since last BUY12.66%
upturn advisory
SELL
SELL since 2 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/18/2025: BCRX (1-star) is a SELL. SELL since 2 days. Profits (12.66%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $16.58

Year Target Price $16.58

Analyst’s Price TargetsFor last 52 week
$16.58Target price
Low$6.01
Current$9.96
high$11.31

Analysis of Past Performance

Type Stock
Historic Profit -22.12%
Avg. Invested days 23
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.96B USD
Price to earnings Ratio -
1Y Target Price 17.44
Price to earnings Ratio -
1Y Target Price 17.44
Volume (30-day avg) -
Beta 1.1
52 Weeks Range 6.01 - 11.31
Updated Date 06/29/2025
52 Weeks Range 6.01 - 11.31
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.26

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -10.62%
Operating Margin (TTM) 14.59%

Management Effectiveness

Return on Assets (TTM) 4.54%
Return on Equity (TTM) -1925.37%

Valuation

Trailing PE -
Forward PE 53.48
Enterprise Value 2456529537
Price to Sales(TTM) 3.89
Enterprise Value 2456529537
Price to Sales(TTM) 3.89
Enterprise Value to Revenue 4.88
Enterprise Value to EBITDA 51.62
Shares Outstanding 209250000
Shares Floating 207019666
Shares Outstanding 209250000
Shares Floating 207019666
Percent Insiders 1.2
Percent Institutions 85.56

Analyst Ratings

Rating 4.42
Target Price 16.58
Buy 5
Strong Buy 6
Buy 5
Strong Buy 6
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

BioCryst Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

BioCryst Pharmaceuticals Inc. was founded in 1986. It has focused on discovering, developing, and commercializing novel small-molecule medicines that address unmet medical needs. Initially focused on structure-guided drug design, BioCryst has evolved into a commercial-stage biopharmaceutical company.

business area logo Core Business Areas

  • Hereditary Angioedema (HAE): BioCryst's primary focus is on HAE, with ORLADEYOu00ae (berotralstat) as its main product. This segment encompasses the development, manufacturing, and commercialization of treatments for HAE and related conditions.
  • Rare Diseases: BioCryst is expanding its portfolio to include treatments for other rare diseases, leveraging its expertise in small-molecule drug development. It has programs targeting complement-mediated diseases.

leadership logo Leadership and Structure

The company is led by Jon Stonehouse (CEO). Its organizational structure includes research and development, commercial operations, finance, and administrative functions. The board of directors provides oversight and strategic guidance.

Top Products and Market Share

overview logo Key Offerings

  • ORLADEYOu00ae (berotralstat): ORLADEYO is an oral, once-daily therapy for the prevention of HAE attacks in adult and pediatric patients 12 years and older. It has captured a significant share of the HAE prophylaxis market. Competitors include Takeda's TAKHZYRO (lanadelumab) and CSL Behring's HAEGARDA (C1 esterase inhibitor).
  • RAPIVABu00ae (peramivir): RAPIVAB is an intravenous neuraminidase inhibitor used to treat acute uncomplicated influenza. Its usage is seasonal. Competitors include Tamiflu (oseltamivir) and Xofluza (baloxavir marboxil).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The rare disease segment is growing, driven by unmet medical needs and orphan drug designations.

Positioning

BioCryst is a commercial-stage biopharmaceutical company with a strong position in the HAE market due to ORLADEYO. The company focuses on developing oral therapies for rare diseases, providing a competitive advantage.

Total Addressable Market (TAM)

The HAE market is estimated to be worth several billion USD annually. BioCryst, with ORLADEYO, aims to capture a significant portion of this TAM. The total addressable market for complement mediated diseases is potentially even larger.

Upturn SWOT Analysis

Strengths

  • Strong position in the HAE market with ORLADEYO
  • Oral therapy providing convenience for patients
  • Experienced management team
  • Focus on rare diseases with unmet medical needs
  • Strong intellectual property portfolio

Weaknesses

  • Reliance on a limited number of products
  • Competition from established therapies
  • Potential for generic erosion
  • Dependence on successful clinical trials for pipeline products
  • Smaller market capitalization compared to competitors

Opportunities

  • Expansion into new indications and rare diseases
  • Geographic expansion
  • Strategic partnerships and collaborations
  • Development of next-generation therapies
  • Increasing awareness and diagnosis of HAE

Threats

  • Competition from existing and emerging therapies
  • Regulatory hurdles and delays
  • Pricing pressures and reimbursement challenges
  • Clinical trial failures
  • Adverse events or safety concerns

Competitors and Market Share

competitor logo Key Competitors

  • TAK
  • CSL

Competitive Landscape

BioCryst has an advantage with its oral therapy, ORLADEYO, which offers convenience compared to injectable competitors. However, competitors like Takeda and CSL Behring have established market presence and brand recognition.

Growth Trajectory and Initiatives

Historical Growth: BioCryst has experienced significant revenue growth driven by the launch and adoption of ORLADEYO.

Future Projections: Analyst estimates project continued revenue growth for ORLADEYO and potential contributions from pipeline products. Profitability is expected to improve over time.

Recent Initiatives: Recent initiatives include expanding the commercial reach of ORLADEYO, advancing pipeline programs in complement-mediated diseases, and exploring strategic partnerships.

Summary

BioCryst is a growing biopharmaceutical company with a strong position in the HAE market thanks to ORLADEYO. The company is seeing increasing revenue and approaching profitability. BioCryst needs to continue to innovate and develop its pipeline, while also managing competition from established players.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Investor Presentations
  • Analyst Reports
  • Industry Research Reports
  • Company Website

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BioCryst Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Durham, NC, United States
IPO Launch date 1994-03-03
CEO, President & Executive Director and Interim CFO, Principal Accounting Officer Mr. Jon P. Stonehouse
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 580
Full time employees 580

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.